Literature DB >> 1532540

Plasma endothelin in chronic heart failure.

J J McMurray1, S G Ray, I Abdullah, H J Dargie, J J Morton.   

Abstract

BACKGROUND: Endothelins are recently characterized vasoconstrictor peptides. As chronic heart failure (CHF) is characterized by peripheral arteriolar and renal vasoconstriction, we have measured venous plasma endothelin-like immunoreactivity ("endothelin") in patients with this syndrome. METHODS AND
RESULTS: Compared with age- and sex-matched healthy volunteers (mean +/- SEM plasma endothelin concentration 6.4 +/- 0.3 pmol/l, n = 16), patients with severe CHF had elevated peripheral venous endothelin concentrations (12.4 +/- 0.6 pmol/l, n = 47, p less than 0.01). Plasma endothelin did not increase with exercise in normal subjects or in patients. Plasma endothelin concentration (mean, 13.4 +/- 0.9 pmol/l) did not correlate with plasma atrial natriuretic factor concentration (mean, 88.9 +/- 11.9 pg/ml) in patients with CHF (n = 21). There was also no correlation between plasma endothelin and serum urea or between endothelin and serum creatinine in patients with CHF (n = 34). There was, however, significant renal extraction of endothelin (aorta, 11.1 +/- 0.8 pmol/l; renal vein, 8.8 +/- 0.6 pmol/ml; p = 0.02) in patients with CHF (n = 13).
CONCLUSIONS: Evidence suggests that circulatory endothelin concentrations in the range 5-40 pmol/l are vasoactive. Consequently, the endothelin concentrations found in patients with CHF may be of pathophysiological significance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532540     DOI: 10.1161/01.cir.85.4.1374

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  78 in total

1.  The role of endothelin in the pathogenesis of heart failure.

Authors:  John R Teerlink
Journal:  Curr Cardiol Rep       Date:  2002-05       Impact factor: 2.931

Review 2.  Bosentan and the endothelin system in congestive heart failure.

Authors:  S H Ellahham; V Charlon; Z Abassi; K A Calis; W K Choucair
Journal:  Clin Cardiol       Date:  2000-11       Impact factor: 2.882

Review 3.  Heart failure in 10 years time: focus on pharmacological treatment.

Authors:  J J V McMurray
Journal:  Heart       Date:  2002-10       Impact factor: 5.994

Review 4.  Is too much neurohormonal blockade harmful?

Authors:  Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2004-05       Impact factor: 2.931

Review 5.  Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure.

Authors:  H Krum; R Denver; A Tzanidis; P Martin
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

6.  Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure.

Authors:  N C Davidson; W J Coutie; D J Webb; A D Struthers
Journal:  Heart       Date:  1996-06       Impact factor: 5.994

Review 7.  Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?

Authors:  L E Spieker; G Noll; F T Ruschitzka; T F Lüscher
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

Review 8.  Endothelins: pathophysiology and treatment implications in chronic heart failure.

Authors:  John R Teerlink
Journal:  Curr Heart Fail Rep       Date:  2005-12

9.  Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure.

Authors:  Matthew R G Taylor; Dobromir Slavov; Kurt Humphrey; Lan Zhao; Jennifer Cockroft; Xiao Zhu; Philip Lavori; Michael R Bristow; Luisa Mestroni; Laura C Lazzeroni
Journal:  Pharmacogenet Genomics       Date:  2009-01       Impact factor: 2.089

Review 10.  Endothelin and heart failure.

Authors:  P Nambi; M Clozel; G Feuerstein
Journal:  Heart Fail Rev       Date:  2001-12       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.